Loading...
Market
Will TG Therapeutics secure a partnership or acquisition deal by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from TG Therapeutics or financial news outlets
Story
TG Therapeutics ($TGTX) Reports Positive ENHANCE Phase 3b Data on Briumvi for Multiple Sclerosis
Oct 14, 2024, 11:37 AM
TG Therapeutics ($TGTX) has released new data from its ENHANCE Phase 3b study, showing that rapid 30-minute infusions of Briumvi (ublituximab-xiiy) are well tolerated in patients with relapsing forms of multiple sclerosis. This comes amid comparisons with SubQ Ocrevus, which requires a 10-minute delivery of 23ml of fluid under the skin, potentially causing discomfort and bruising. The total treatment time for SubQ Ocrevus is approximately 1.5 hours, compared to 4.5 hours for IV Ocrevus. KOLS do not favor SubQ Ocrevus, and the Briumvi switching trial is showing promising results.
View original story
Similar markets
Increases by less than 10% • 25%
Increases by 10% to 25% • 25%
Increases by 25% to 50% • 25%
Increases by more than 50% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
